论文部分内容阅读
目的评价89SrC l2对乳腺癌转移性骨痛的临床疗效。方法观察乳腺癌骨转移并伴有不同程度骨痛患者88例,使用89SrC l2静脉注射治疗,观察其镇痛效果、骨转移灶的变化及不良反应等。结果治疗后骨痛减轻或消失75例,总有效率为85.2%;治疗后骨显像有53.4%(47例)骨转移灶代谢减低,治疗前后RO I比值差异具有统计学意义(P<0.05)。未见明显骨髓抑制与肝肾脏功能损伤。结论89Sr对缓解乳腺癌骨转移瘤疼痛有较好疗效,并有一定的治疗作用,副作用小,可重复用药。
Objective To evaluate the clinical effect of 89SrC12 on metastatic bone pain in breast cancer. Methods Eighty-eight patients with bone metastasis of breast cancer accompanied with varying degrees of bone pain were treated with 89SrCl 2 intravenous injection. The analgesic effect, changes of bone metastases and adverse reactions were observed. Results After treatment, the pain relief reduced or disappeared in 75 cases, the total effective rate was 85.2%. After the treatment, 53.4% (47 cases) of bone metastases reduced metabolism, the difference of ROI before and after treatment was statistically significant (P <0.05 ). No obvious myelosuppression and liver and kidney dysfunction. Conclusion 89Sr has a good curative effect on alleviating the pain of bone metastases of breast cancer, and has some therapeutic effects. The side effects are small and can be reused.